vTv Therapeutics Inc.
VTVT
$22.74
$7.8953.13%
Weiss Ratings | VTVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Rating | ||||
Reward Index | Very Weak | |||
Risk Index | Weak | |||
Risk Grade | D | |||
Reward Grade | E | |||
Rating Factors | VTVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Dividend Index | -- | |||
Growth Index | Weak | |||
Efficiency Index | Very Weak | |||
Solvency Index | Excellent | |||
Total Return Index | Weak | |||
Volatility Index | Weak | |||
Beta / Standard Deviation | VTVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Beta | 1.11 | |||
Price History | VTVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
7-Day Total Return | 47.75% | |||
30-Day Total Return | 44.66% | |||
60-Day Total Return | 46.99% | |||
90-Day Total Return | 62.43% | |||
Year to Date Total Return | 67.55% | |||
1-Year Total Return | 13.02% | |||
2-Year Total Return | -25.20% | |||
3-Year Total Return | -15.35% | |||
5-Year Total Return | -65.12% | |||
52-Week High % Change | -26.62% | |||
52-Week Low % Change | 87.62% | |||
Price | VTVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
52-Week High Price | $30.99 | |||
52-Week Low Price | $12.12 | |||
52-Week Low Price (Date) | Jul 29, 2024 | |||
52-Week High Price (Date) | Mar 21, 2024 | |||
Valuation | VTVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Market Cap | 59.40M | |||
Enterprise Value | 20.86M | |||
Price/Earnings (TTM) | -- | |||
Earnings Per Share (TTM) | -7.63 | |||
Earnings Per Share Growth | -26.47% | |||
Price/Earnings To Growth | -- | |||
Price/Sales (TTM) | 59.40 | |||
Price/Book (Q) | 3.96 | |||
Enterprise Value/Revenue (TTM) | 20.86 | |||
Price | $22.74 | |||
Enterprise Value/EBITDA (TTM) | -0.87 | |||
Enterprise Value/EBIT | -0.87 | |||
Market Cap Category | Micro Cap | |||
Dividends and Shares | VTVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Shares Outstanding | 2.61M | |||
Dividend Yield | -- | |||
Div. Per Share (Most Recent) | -- | |||
Dividend Per Share (TTM) | -- | |||
Payout Ratio (TTM) | -- | |||
Dividend Per Share (Most Recent) | -- | |||
Company Info | VTVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Phone Number | 336 841 0300 | |||
Address | 3980 Premier Drive High Point, NC 27265 | |||
Website | vtvtherapeutics.com | |||
Country | United States | |||
Year Founded | 2015 | |||
Profitability | VTVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Operating Margin (TTM) | -2,399.50% | |||
Profit Margin | -1,830.60% | |||
Management Effectiveness | VTVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Return on Assets | -51.64% | |||
Return on Equity | -- | |||
Income Statement | VTVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Revenue (TTM) | 1.00M | |||
Total Revenue (TTM) | 1.00M | |||
Revenue Per Share | $0.38 | |||
Gross Profit (TTM) | -7.23M | |||
EBITDA (TTM) | -23.91M | |||
EBIT (TTM) | -24.00M | |||
Net Income (TTM) | -18.31M | |||
Net Income Avl. to Common (TTM) | -18.31M | |||
Total Revenue Growth (Q YOY) | -- | |||
Earnings Growth (Q YOY) | 31.62% | |||
EPS Diluted (TTM) | -7.63 | |||
EPS Diluted Growth (Q YOY) | 42.63% | |||
Balance Sheet | VTVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash and Short-Term Inv. (Q) | 41.66M | |||
Cash Per Share (Q) | $15.95 | |||
Total Current Assets (Q) | 42.96M | |||
Total Preferred Equity (Q) | -- | |||
Total Equity (Q) | 17.91M | |||
Current Ratio (Q) | 6.687 | |||
Book Value Per Share (Q) | $5.75 | |||
Total Assets (Q) | 43.16M | |||
Total Current Liabilities (Q) | 6.42M | |||
Total Debt (Q) | 213.00K | |||
Total Liabilities (Q) | 25.25M | |||
Total Common Equity (Q) | 15.01M | |||
Cash Flow | VTVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash from Investing (TTM) | 4.40M | |||
Cash from Financing (TTM) | 52.33M | |||
Net Change in Cash (TTM) | 33.33M | |||
Levered Free Cash Flow (TTM) | -15.40M | |||
Cash from Operations (TTM) | -23.40M | |||